Melanotan I (MT-1)

10mg Vial

2 September 2026Updated 2 September 2026

Melanotan I (MT-1)

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Melanotan I (MT-1).

Create free account Member login

Full range of benefits for Melanotan I (MT-1)

Stimulates eumelanin production for increased skin pigmentation

Promotes tanning with less UV exposure

May enhance melanin-mediated photoprotection

May reduce phototoxic pain episodes in erythropoietic protoporphyria

May lower UV-induced erythema and sunburn susceptibility

May augment phototherapy-induced repigmentation in vitiligo

May decrease UV-induced DNA damage and oxidative stress (limited evidence)

May improve sun tolerance and daily functioning in photosensitive patients

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 15 known interactions

Synergistic(2)Compatible(4)Monitor(4)Avoid(5)

Use with professional oversight

Photosensitizing medications (e.g., tetracyclines, sulfonamides)

These agents can increase risk of phototoxic reactions despite pigmentation, so clinicians should monitor for skin reactions and counsel on UV avoidance.

Immunosuppressants (e.g., azathioprine, cyclosporine)

Concomitant immunosuppression may increase skin cancer risk and modify cutaneous responses, warranting regular dermatologic surveillance when combined with MT-1.

Systemic retinoids (isotretinoin, acitretin)

Retinoids can alter skin integrity and photosensitivity, so monitor tolerance and skin adverse effects if used with MT-1.

Concurrent phototherapy regimens (PUVA/NB-UVB)

When MT-1 is used with any UV-based therapy, monitor cumulative UV dose, skin pigmentation response and long-term photocarcinogenic risk, adjusting treatment schedules as needed.

All interaction categories

Synergistic (2)

Narrowband UVB phototherapy: Concomitant NB-UVB can enhance eumelanin production induced by MT-1, producing greater cutaneous pigmentation and improved photoprotection under supervised dosing.
Controlled sunlight exposure: Planned, limited UV exposure after MT-1 administration synergises with α-MSH receptor activation to increase melanin synthesis and extend time to phototoxicity or sunburn.

Compatible (4)

Topical sunscreens: Sunscreen use is physiologically compatible with MT-1 and should be continued to reduce UV injury despite increased pigmentation.
Emollients and topical moisturizers: Routine topical skin care agents do not alter MT-1 pharmacology and are safe to use concomitantly to manage dryness or irritation.
Analgesics (paracetamol/NSAIDs): Analgesics used for management of phototoxic pain have no known pharmacodynamic or metabolic interaction with MT-1 and are generally compatible.
Oral contraceptives: Hormonal contraceptives have no established interaction with MT-1 and may be co-administered without anticipated effect on pigmentation response.

Monitor (4)

Photosensitizing medications (e.g., tetracyclines, sulfonamides): These agents can increase risk of phototoxic reactions despite pigmentation, so clinicians should monitor for skin reactions and counsel on UV avoidance.
Immunosuppressants (e.g., azathioprine, cyclosporine): Concomitant immunosuppression may increase skin cancer risk and modify cutaneous responses, warranting regular dermatologic surveillance when combined with MT-1.
Systemic retinoids (isotretinoin, acitretin): Retinoids can alter skin integrity and photosensitivity, so monitor tolerance and skin adverse effects if used with MT-1.
Concurrent phototherapy regimens (PUVA/NB-UVB): When MT-1 is used with any UV-based therapy, monitor cumulative UV dose, skin pigmentation response and long-term photocarcinogenic risk, adjusting treatment schedules as needed.

Avoid (5)

Melanotan II (MT-II): Co-administration with other melanocortin agonists like MT-II may produce additive melanogenic and off-target effects (e.g., blood pressure, sexual function), so combined use should be avoided or closely supervised.
Psoralens (PUVA therapy): Psoralen plus UVA increases long-term photocarcinogenic risk and may interact with MT-1–mediated pigmentation pathways, requiring careful risk–benefit assessment before combination.
Photosensitizing systemic drugs (amiodarone, certain antibiotics): Because MT-1 may reduce acute sunburn perception, use with strong photosensitizers could mask injury and lead to severe phototoxicity, so evaluate risks prior to co-prescribing.
Immunosuppressive therapy (calcineurin inhibitors, biologics): Given the theoretical increased risk of skin malignancy with immunosuppression, clinicians should exercise caution and ensure enhanced dermatologic surveillance when combining these agents with MT-1.
Pregnancy and breastfeeding: There are limited safety data for MT-1 in pregnancy or lactation, so avoid use or administer only after a careful risk–benefit discussion and specialist consultation.